October 2010 Newsletter Now Available

Top stories from TTO's October newsletter:

Arch Biopartners Acquires Option to License Anti-Cancer Compounds from CU
Arch Biopartners Inc. announced that it has formed a new American subsidiary, Colorado Cancer Therapeutics ("CCT") with leading University of Colorado biochemists Dr. Lajos Gera and Dr. Robert Hodges. Additionally, CCT has acquired an option to enter into an exclusive license to commercialize specific pre-clinical, anti-cancer compounds invented at the University of Colorado and Emory University by Drs. Lajos Gera, Robert Hodges, Paul Bunn, John Stewart, Dan Chan, and Leland Chung and Daqing Wu.

Colorado BioScience Association Recognizes TTO as 2010 Partner of the Year
The Colorado BioScience Association (CBSA) honored the outstanding bioscience companies and individuals in the state during its 2010 Annual Awards Dinner held in conjunction with the BioWest Conference. CU TTO, along with the Colorado State University Technology Transfer Office, received the 2010 Partner of the Year Award.

Omni Bio Announces First Infusion in Phase I/II Clinical Trial of Alpha-1 Antitrypsin in Recently Diagnosed Diabetic Patients
CU licensee Omni Bio Pharmaceutical, Inc. announced in October that the first patient has been infused in its FDA-cleared Phase I/II human clinical trial of Alpha-1 antitrypsin ("AAT") in recently diagnosed Type 1 diabetics at the Barbara Davis Center for Childhood Diabetes at the University of Colorado Denver Anschutz Medical Campus.

Read the full newsletter, or sign up to receive a monthly email update.